Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Medivir

DB:MVR
Snowflake Description

Flawless balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MVR
DB
SEK314M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology. The last earnings update was 53 days ago. More info.


Add to Portfolio Compare Print
  • Medivir has significant price volatility in the past 3 months.
MVR Share Price and Events
7 Day Returns
3.6%
DB:MVR
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
-
DB:MVR
-13.2%
DE Biotechs
-20.9%
DE Market
MVR Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Medivir (MVR) 3.6% -17.6% 1.9% - - -86.9%
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • No trading data on MVR.
  • No trading data on MVR.
Price Volatility
MVR
Industry
5yr Volatility vs Market

Value

 Is Medivir undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Medivir. This is due to cash flow or dividend data being unavailable. The share price is €1.162.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Medivir's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Medivir's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:MVR PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in SEK SEK-5.08
OM:MVIR B Share Price ** OM (2020-04-03) in SEK SEK12.92
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Medivir.

DB:MVR PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:MVIR B Share Price ÷ EPS (both in SEK)

= 12.92 ÷ -5.08

-2.54x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Medivir is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Medivir is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Medivir's expected growth come at a high price?
Raw Data
DB:MVR PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.54x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
-4%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Medivir, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Medivir's assets?
Raw Data
DB:MVR PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in SEK SEK7.60
OM:MVIR B Share Price * OM (2020-04-03) in SEK SEK12.92
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:MVR PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:MVIR B Share Price ÷ Book Value per Share (both in SEK)

= 12.92 ÷ 7.60

1.7x

* Primary Listing of Medivir.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Medivir is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Medivir's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Medivir has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Medivir expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Medivir expected to grow at an attractive rate?
  • Unable to compare Medivir's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Medivir's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Medivir's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:MVR Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:MVR Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts -4%
DB:MVR Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 37.5%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:MVR Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:MVR Future Estimates Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 338 -29 1
2023-12-31 9 -252 1
2022-12-31 10 -210 -196 2
2021-12-31 193 -255 -65 2
2020-12-31 10 -136 -129 1
2020-04-06
DB:MVR Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2019-12-31 9 -149 -123
2019-09-30 21 -196 -206
2019-06-30 22 -241 -254
2019-03-31 21 -288 -333
2018-12-31 24 -319 -350
2018-09-30 15 -337 -339
2018-06-30 17 -322 -348
2018-03-31 23 -322 -348
2017-12-31 37 -358 -360
2017-09-30 42 -341 -379
2017-06-30 63 -315 -353
2017-03-31 90 -270 -320

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Medivir is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Medivir's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:MVR Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Medivir Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:MVR Future Estimates Data
Date (Data in SEK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -0.31 -0.31 -0.31 1.00
2023-12-31 -2.85 -2.85 -2.85 1.00
2022-12-31 -5.16 -2.22 -8.10 2.00
2021-12-31 -1.29 8.44 -10.06 3.00
2020-12-31 -4.24 -3.09 -5.39 2.00
2020-04-06
DB:MVR Past Financials Data
Date (Data in SEK Millions) EPS *
2019-12-31 -5.08
2019-09-30 -8.48
2019-06-30 -10.46
2019-03-31 -13.72
2018-12-31 -14.62
2018-09-30 -14.76
2018-06-30 -15.82
2018-03-31 -15.98
2017-12-31 -16.40
2017-09-30 -16.03
2017-06-30 -13.97
2017-03-31 -12.25

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Medivir will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Medivir's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Medivir has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Medivir performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Medivir's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Medivir does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Medivir's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Medivir's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Medivir's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Medivir Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:MVR Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 8.70 -123.40 35.00
2019-09-30 20.96 -206.01 319.89
2019-06-30 22.26 -254.11 335.69
2019-03-31 21.26 -333.31 356.29
2018-12-31 23.86 -350.31 365.19
2018-09-30 14.54 -338.82 177.46
2018-06-30 16.64 -347.52 243.36
2018-03-31 23.34 -348.32 318.56
2017-12-31 36.64 -360.22 392.06
2017-09-30 42.24 -378.76 424.55
2017-06-30 62.84 -353.16 416.45
2017-03-31 90.24 -319.96 411.75
2016-12-31 93.04 -294.86 400.35
2016-09-30 -15.73 -261.79 244.44 70.28
2016-06-30 70.07 -217.89 205.84 140.68
2016-03-31 278.97 -94.69 154.04 212.18
2015-12-31 474.27 31.71 105.54 278.38
2015-09-30 950.19 267.64 173.80 284.45
2015-06-30 1,456.49 651.74 168.90 266.95
2015-03-31 1,774.69 915.64 162.70 259.85
2014-12-31 1,766.99 1,132.74 166.10 245.75
2014-09-30 1,537.15 1,004.71 152.55 230.49
2014-06-30 999.55 620.21 146.35 223.89
2014-03-31 476.25 228.71 136.45 216.09
2013-12-31 446.15 16.01 122.35 219.39
2013-09-30 347.85 -73.90 110.52 218.95
2013-06-30 304.25 -119.30 107.32 219.15

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Medivir has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Medivir has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Medivir improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Medivir's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Medivir has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Medivir's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Medivir's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Medivir is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Medivir's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Medivir's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Medivir has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Medivir Company Filings, last reported 3 months ago.

DB:MVR Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 184.50 0.00 134.60
2019-09-30 216.50 0.00 158.50
2019-06-30 239.50 0.00 191.90
2019-03-31 251.70 0.00 228.70
2018-12-31 307.61 0.00 286.28
2018-09-30 422.30 0.00 357.20
2018-06-30 493.80 0.00 438.60
2018-03-31 586.30 0.00 522.70
2017-12-31 514.06 0.00 467.78
2017-09-30 617.10 0.00 557.80
2017-06-30 698.70 0.00 624.10
2017-03-31 790.60 0.00 708.90
2016-12-31 1,732.91 0.00 1,698.48
2016-09-30 1,318.70 0.00 955.00
2016-06-30 1,370.70 0.00 997.40
2016-03-31 1,410.10 0.00 1,039.50
2015-12-31 1,450.11 0.00 1,077.94
2015-09-30 1,492.90 0.00 1,118.10
2015-06-30 1,502.50 0.00 1,043.40
2015-03-31 1,448.20 0.00 998.40
2014-12-31 1,982.60 40.00 1,395.62
2014-09-30 1,839.30 40.00 896.40
2014-06-30 1,464.70 40.00 430.40
2014-03-31 1,136.90 40.00 341.80
2013-12-31 852.59 40.00 402.22
2013-09-30 833.70 0.00 337.70
2013-06-30 843.70 25.00 279.90
  • Medivir has no debt.
  • Medivir has no debt compared to 5 years ago when it was 2%.
  • Medivir has no debt, it does not need to be covered by operating cash flow.
  • Medivir has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Medivir's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Medivir has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Medivir's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Medivir dividends. Estimated to be 0% next year.
If you bought €2,000 of Medivir shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Medivir's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Medivir's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:MVR Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:MVR Future Dividends Estimate Data
Date (Data in SEK) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 0.00 1.00
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2020-04-06

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Medivir has not reported any payouts.
  • Unable to verify if Medivir's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Medivir's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Medivir has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Medivir's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Medivir's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Medivir afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Medivir has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Medivir's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Uli Hacksell
COMPENSATION SEK2,332,800
AGE 69
TENURE AS CEO 1.5 years
CEO Bio

Dr. Uli Hacksell, Ph.D., serves as Chief Executive Officer and President of Medivir AB (publ) and served as its Acting Chief Executive Officer since October 15, 2018. He has been Director of Active Biotech AB (publ) since May 23, 2019. He has been Chairman of Adhera Therapeutics, Inc. since July 1, 2018. Dr. Hacksell has been the Chairman of Glionova AB since June 1, 2015. He was Chairman of Cerecor Inc. since May 22, 2015 until April 15, 2019. He has been Director of Cerecor Inc. since May 22, 2015. Dr. Hacksell served as the Chief Executive Officer and President of Cerecor Inc. from January 1, 2016 to August 14, 2017. Dr. Hacksell served as the Chief Executive Officer of ACADIA Pharmaceuticals Inc. from September 2000 to March 11, 2015 and served as its President until March 11, 2015. Dr. Hacksell has over 20 years of international R&D management experience from both large pharmaceutical and biotech companies as well as over 10 years of experience as public company CEO. Dr. Hacksell served as the Chief Financial Officer and Chief Accounting Officer of ACADIA Pharmaceuticals Inc., from April 18, 2014 to July 2014. He served as an Executive Vice President of Drug Discovery of ACADIA from February 1999 to September 2000. From August 1991 to February 1999, Dr. Hacksell held various senior executive positions at Astra, he served as Vice President of Drug Discovery & Technology and President of Astra Draco. From August 1991 to May 1994, he served as Vice President of CNS Preclinical R&D at Astra Arcus. He served as Chairman of SynActPharma A/S until 2015. Dr. Hacksell served as the Chairman of Action Pharma A/S since 2003. Dr. Hacksell serves as a Board Member of SynAct Pharma A/S. He has been a Board Member of InDex Pharmaceuticals AB since June 2015. He has been Director at InDex Pharmaceuticals Holding AB (publ) since 2015. He has been a Director of Medivir AB (publ) since May 3, 2018 and serves as its Acting CEO since October 15, 2018. He serves as a Member of Advisory Board at Medical Products Agency. Dr. Hacksell served as a Director of ActionPharma A/S. He served as a Member of Investment Advisory Board of Karolinska Development AB (publ). Dr. Hacksell served as a Director of SLS Invest. Dr. Hacksell held the positions of Professor of Organic Chemistry and Department Chairman at Uppsala University and also served as Chairman and Vice Chairman of the European Federation of Medicinal Chemistry. He served as a Director of ACADIA Pharmaceuticals Inc. from September 2000 to March 2015. He has authored about 200 scientific articles. Dr. Hacksell received a Ph.D. in Medicinal Chemistry in 1981, a Master of Pharmacy in 1976 from Uppsala University and holds an MPH.

CEO Compensation
  • Insufficient data for Uli to compare compensation growth.
  • Uli's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Medivir management team in years:

1.3
Average Tenure
60.5
Average Age
  • The average tenure for the Medivir management team is less than 2 years, this suggests a new team.
Management Team

Uli Hacksell

TITLE
CEO, President & Director
COMPENSATION
SEK2M
AGE
69
TENURE
1.5 yrs

Magnus Christensen

TITLE
Chief Financial Officer
AGE
45
TENURE
0.7 yrs

Christina Herder

TITLE
Executive VP & COO
AGE
58
TENURE
1.3 yrs

Fredrik Öberg

TITLE
Chief Scientific Officer
TENURE
0.6 yrs

Linda Basse

TITLE
Chief Medical Officer
AGE
63
TENURE
1.5 yrs

Karin Tunblad

TITLE
Senior Principal Scientist & MIV-818 Project Leader
Board of Directors Tenure

Average tenure and age of the Medivir board of directors in years:

1.9
Average Tenure
64.5
Average Age
  • The average tenure for the Medivir board of directors is less than 3 years, this suggests a new board.
Board of Directors

Helena Levander

TITLE
Chairman
AGE
62
TENURE
0.9 yrs

Uli Hacksell

TITLE
CEO, President & Director
COMPENSATION
SEK2M
AGE
69
TENURE
1.9 yrs

Bengt Julander

TITLE
Independent Director
AGE
66
TENURE
2.9 yrs

Bengt Westermark

TITLE
Independent Director
AGE
74
TENURE
2.9 yrs

Lennart Hansson

TITLE
Director
AGE
63
TENURE
1.9 yrs

An van Es-Johansson

TITLE
Independent Director
AGE
59
TENURE
0.9 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Medivir individual insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
20. Feb 20 Buy Uli Hacksell Individual 19. Feb 20 19. Feb 20 20,000 €1.38 €27,480
20. Dec 19 Buy Uli Hacksell Individual 18. Dec 19 18. Dec 19 20,000 €1.13 €22,673
17. Dec 19 Buy Helena Levander Individual 17. Dec 19 17. Dec 19 23,500 €1.08 €25,209
19. Jun 19 Buy Linc AB Company 19. Jun 19 19. Jun 19 50,000 €1.78 €88,775
13. Jun 19 Buy Bengt Westermark Individual 13. Jun 19 13. Jun 19 2,000 €1.80 €3,608
X
Management checks
We assess Medivir's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Medivir has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology. The company markets Xerclear for use in the treatment of labial herpes under the Zoviduo name. It develops Remetinostat, which has completed phase II clinical trial for treating cutaneous T-cell lymphoma, as well as in phase II clinical trial for treating basal cell carcinoma; and Birinapant that is in phase II clinical trial for treating colorectal cancer. The company also develops MIV-818, which is in phase Ia clinical trial for treating liver cancer; MIV-828, a candidate drug for treating blood cancer; MIV-711, which is in phase II clinical trial for treating osteoarthritis; and MIV-802, a nucleotide-based drug candidate for treating hepatitis C infections. It sells its products in Sweden, the Nordic region, Europe, the United States, and the rest of the world. Medivir AB (publ) was founded in 1988 and is based in Huddinge, Sweden.

Details
Name: Medivir AB (publ)
MVR
Exchange: DB
Founded: 1988
SEK28,575,425
24,288,000
Website: http://www.medivir.com
Address: Medivir AB (publ)
Lunastigen 7,
Huddinge,
Stockholm County, 141 22,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM MVIR B Class B Shares OMX Nordic Exchange Stockholm SE SEK 15. Nov 1996
OTCPK MVRB.F Class B Shares Pink Sheets LLC US USD 15. Nov 1996
DB MVR Class B Shares Deutsche Boerse AG DE EUR 15. Nov 1996
LSE 0GP7 Class B Shares London Stock Exchange GB SEK 15. Nov 1996
BATS-CHIXE MVIRBs Class B Shares BATS 'Chi-X Europe' GB SEK 15. Nov 1996
Number of employees
Current staff
Staff numbers
14
Medivir employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/06 01:19
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/03/03
Last earnings filing: 2020/02/13
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.